LEGN
Legend Biotech Corporation
LEGN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over LEGN overall, supported by stronger fundamentals and lower modeled downside.
LEGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Unavailable |
LEGN's revenue is currently healthy, and its profitability is stable, but its cash flow is weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LEGN PE Valuation
LEGN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LEGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for LEGN, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LEGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.40 | +$0.82 |
| Q1 2026 | -$0.92 | +$0.06 |
| Q4 2025 | -$0.89 | -$0.02 |
| Q3 2025 | -$0.65 | +$1.09 |
| Q2 2025 | -$1.22 | +$0.18 |
| Q1 2025 | -$0.98 | +$1.46 |
| Q4 2024 | -$0.87 | +$2.09 |
| Q3 2024 | -$1.74 | +$1.27 |
LEGN is still losing money, but far less than before: $0.40 per share over the past year, against $3.32 at its worst in early 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LEGN on earnings quality, reporting a profit while its opponent remains loss making.
LEGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $387.5M | +52% |
| Q1 2026 | $305.1M | +56% |
| Q4 2025 | $306.4M | +64% |
| Q3 2025 | $272.3M | +70% |
| Q2 2025 | $255.1M | +37% |
| Q1 2025 | $195.1M | +108% |
| Q4 2024 | $186.5M | +135% |
| Q3 2024 | $160.2M | +67% |
LEGN has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 15% | +64 points |
| Q1 2026 | -16% | +35 points |
| Q4 2025 | -6.7% | -28 points |
| Q3 2025 | -16% | +28 points |
| Q2 2025 | -49% | -26 points |
| Q1 2025 | -51% | +13 points |
| Q4 2024 | 22% | +173 points |
| Q3 2024 | -44% | +53 points |
LEGN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LEGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$41.5M | -$19.2M |
| Q1 2026 | -$111.3M | -$5.6M |
| Q4 2025 | -$126.6M | -$42.1M |
| Q3 2025 | $23.8M | +$101.7M |
| Q2 2025 | -$22.3M | -$17.2M |
| Q1 2025 | -$105.8M | -1240% |
| Q4 2024 | -$84.5M | +$18M |
| Q3 2024 | -$77.9M | -$11.6M |
LEGN has burned cash in almost every quarter: −$256M over the past year, against −$290M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LEGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
LEGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +9.1M shares |
| 1 year | -47% | -174M shares |
| 3 years | +11% | +18.5M shares |
| 5 years | +40% | +55.3M shares |
| Available history | +93% | +93.6M shares |
LEGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LEGN Net Leverage
LEGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LEGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 63.0 | Neutral |
LEGN's weekly RSI is 44 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LEGN PE vs Healthcare Sector
LEGN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LEGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 5.9% below |
| 20 week MA | $20.9 | 11% below |
| 50 week MA | $22.1 | 16% below |
| 100 week MA | $28.2 | 34% below |
| 200 week MA | $42.3 | 56% below |
LEGN is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LEGN on trend strength, trading above more of its moving averages.
LEGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.0 | $29.5 | -20% |
| 2021 | $29.5 | $48.7 | +65% |
| 2022 | $48.7 | $49.8 | +2.3% |
| 2023 | $49.8 | $60.2 | +21% |
| 2024 | $60.2 | $32.5 | -46% |
| 2025 | $32.5 | $22.5 | -31% |
| 2026 YTD | $22.5 | $18.5 | -18% |
LEGN has finished lower in three of the last six years. It's down 18% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LEGN on returns for 2026, with the stronger performance.